William Tanner joined Leerink Swann in 2002 as Head of the Biotechnology Equity Research group. Dr. Tanner was previously with SG Cowen Securities Corp., where he served as Managing Director and Biotechnology Analyst. Before joining SG Cowen, he served as Biotechnology Analyst at the former Vector Securities International and at Principal Financial Securities. Prior to his positions in equity research, Dr. Tanner was a Research Associate at Washington University School of Medicine's Center for Immunology and Department of Pathology. Dr. Tanner received his MBA from the Olin School of Business at Washington University and his Ph.D. in Physiology from Texas A&M University. Dr. Tanner did his post-doctorate work at Monsanto Co. in the department of Molecular Genetics and Mammalian Biology. He was a recipient of the National Research Service Award from the National Institutes of Health and received a postdoctoral fellowship at the Juvenile Diabetes Foundation.